Skip to contentS
Sonoma Pharmaceuticals, Inc.
S
SNOASonoma Pharmaceuticals, Inc. Q3 2022 · 10-Q
Revenue$2.90M$2.90M−41.2% vs Q3 2021 Net Income-$944.00K-$944.00KN/M vs Q3 2021 EPS Diluted-$0.31-$0.31N/M vs Q3 2021 Gross Profit$1,203,000−39.7% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Sonoma Pharmaceuticals, Inc. · CIK 1367083 · Engraved from SEC EDGAR
Operating Cash Flowderived-$326,000N/M Free Cash Flowderived-$327,000N/M Margins · derivedGross margin41.5%+1.0 pt vs Q3 2021
Operating margin-33.0%−30.2 pt vs Q3 2021
Net margin-32.5%−19.4 pt vs Q3 2021
ended Dec 31, 2021 · filed Feb 11, 2022 · 42 d after period end